Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2013 | 10-2013 | 12-2012 | 10-2012 | 12-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | N/A | 52 | N/A | 26 | 26 |
| Receivables | N/A | 25 | 7 | 7 | 7 |
| Other current assets | 0 | 13 | 0 | 5 | 5 |
| TOTAL | $N/A | $106 | $7 | $38 | $38 |
| Non-Current Assets | |||||
| PPE Net | N/A | 40 | 0 | N/A | N/A |
| Other Non-Current Assets | 0 | 0 | 0 | 5 | 0 |
| TOTAL | $N/A | $40 | $N/A | $5 | $N/A |
| Total Assets | $N/A | $146 | $7 | $43 | $43 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2 | 15 | 0 | 4 | 0 |
| Accrued Expenses | 180 | N/A | 0 | N/A | N/A |
| TOTAL | $182 | $62 | $N/A | $4 | $4 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $182 | $62 | $N/A | $4 | $4 |
| Shareholders' Equity | |||||
| Common Shares | 1 | 4 | N/A | 3 | N/A |
| Retained earnings | -183 | -3 | N/A | 1 | 1 |
| Other shareholders' equity | 0 | 0 | 0 | 0 | 38 |
| TOTAL | $-182 | $83 | $N/A | $39 | $39 |
| Total Liabilities And Equity | $0 | $146 | $0 | $43 | $43 |